Tempest Therapeutics, Inc. (TPST)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
TPST Insider Trading Activity
TPST Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $100,001 | 3 | 60 |
Sells | $967,033 | 2 | 40 |
Related Transactions
| Brady Stephen R | President and CEO | 1 | $73,850 | 0 | $0 | $73,850 |
| Trojanowski Justin | Corporate Controller | 1 | $16,200 | 0 | $0 | $16,200 |
| Whiting Samuel | Chief Medical Officer | 1 | $9,951 | 0 | $0 | $9,951 |
| Versant Venture Capital VI, L.P. | 10 percent owner | 0 | $0 | 2 | $967,033 | $-967,033 |
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was …
Insider Activity of Tempest Therapeutics, Inc.
Over the last 12 months, insiders at Tempest Therapeutics, Inc. have bought $100,001 and sold $967,033 worth of Tempest Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tempest Therapeutics, Inc. have bought $1.71M and sold $967,033 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Brady Stephen R (President and CEO) — $73,850. Trojanowski Justin (Corporate Controller) — $16,200. Whiting Samuel (Chief Medical Officer) — $9,951.
The last purchase of 35,000 shares for transaction amount of $73,850 was made by Brady Stephen R (President and CEO) on 2024‑07‑03.
List of Insider Buy and Sell Transactions, Tempest Therapeutics, Inc.
| 2024-08-12 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 387,999 2.043% | $1.10 | $426,993 | -1.24% | |
| 2024-08-08 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 400,000 1.814% | $1.35 | $540,040 | -29.44% | |
| 2024-07-03 | Brady Stephen R | President and CEO | 35,000 0.1539% | $2.11 | $73,850 | -53.29% | ||
| 2024-07-02 | Whiting Samuel | Chief Medical Officer | 4,672 0.0207% | $2.13 | $9,951 | -53.17% | ||
| 2024-06-28 | Trojanowski Justin | Corporate Controller | 7,500 0.0338% | $2.16 | $16,200 | -53.88% | ||
| 2022-04-29 | Woiwode Thomas | 2.12M 11.9674% | $2.36 | $5M | -44.60% | |||
| 2022-01-07 | Dubensky Thomas W. | President | 2,000 0.0288% | $4.78 | $9,560 | -47.73% | ||
| 2022-01-06 | Whiting Samuel | Chief Medical Officer | 1,700 0.0243% | $4.80 | $8,168 | -48.40% | ||
| 2016-06-01 | Dipp Michelle | Chief Executive Officer | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | ||
| 2016-06-01 | ALDRICH RICHARD | director | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | ||
| 2016-05-18 | Dipp Michelle | Chief Executive Officer | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | ||
| 2016-05-18 | ALDRICH RICHARD | director | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | ||
| 2016-05-17 | Dipp Michelle | Chief Executive Officer | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | ||
| 2016-05-17 | ALDRICH RICHARD | director | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | ||
| 2016-05-16 | Dipp Michelle | Chief Executive Officer | 20,000 0.0668% | $7.69 | $153,800 | -51.69% | ||
| 2016-05-13 | Dipp Michelle | Chief Executive Officer | 16,295 0.055% | $7.06 | $115,043 | -46.48% | ||
| 2016-05-13 | ALDRICH RICHARD | director | 16,295 0.055% | $7.06 | $115,043 | -46.48% | ||
| 2016-05-12 | Dipp Michelle | Chief Executive Officer | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | ||
| 2016-05-12 | ALDRICH RICHARD | director | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | ||
| 2016-05-11 | Dipp Michelle | Chief Executive Officer | 20,000 0.0709% | $7.64 | $152,800 | -47.08% |
Insider Historical Profitability
| Brady Stephen R | President and CEO | 46376 0.1063% | $39,651.48 | 1 | 0 | |
| Trojanowski Justin | Corporate Controller | 22168 0.0508% | $18,953.64 | 1 | 0 | |
| Whiting Samuel | Chief Medical Officer | 9573 0.0219% | $8,184.92 | 2 | 0 | <0.0001% |
| Westphal Christoph H | 3820571 8.7543% | $3.27M | 2 | 0 | ||
| Longwood Fund, L.P. | 10 percent owner | 3820571 8.7543% | $3.27M | 2 | 0 |
Historical Insider Profitability vs. Competitors
Tempest Therapeutics, Inc. (TPST) | $22,186,116 | 57 | -43.73% | $37.31M |
$140,938,207 | 36 | 14.75% | $41.76M | |
$23,895,365 | 34 | -37.28% | $37.97M | |
$241,165 | 22 | -16.72% | $40.55M | |
$167,476,357 | 20 | -1.54% | $41.64M |
TPST Institutional Investors: Active Positions
| Increased Positions | 22 | +66.67% | 5M | +171.18% |
| Decreased Positions | 12 | -36.36% | 929,854 | -32.7% |
| New Positions | 14 | New | 4M | New |
| Sold Out Positions | 7 | Sold Out | 803,479 | Sold Out |
| Total Postitions | 43 | +30.3% | 7M | +138.48% |
TPST Ownership Change vs Market
Institutional Investor Ownership
| Versant Venture Management, Llc | $2,946.00 | 7.97% | 3.51M | +4M | New | 2024-12-31 |
| Blackrock, Inc. | $464.00 | 1.25% | 551,861 | +274 | +0.05% | 2024-12-31 |
| Jane Street Group, Llc | $414.00 | 1.12% | 493,094 | +493,094 | New | 2024-12-31 |
| Fmr Llc | $363.00 | 0.98% | 431,932 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $298.00 | 0.81% | 354,276 | +134,209 | +60.99% | 2024-12-31 |
| Ubs Group Ag | $164.00 | 0.45% | 195,676 | +187,281 | +2,230.86% | 2024-12-31 |
| Millennium Management Llc | $159.00 | 0.43% | 189,506 | +189,506 | New | 2024-12-31 |
| Vanguard Group Inc | $148.00 | 0.4% | 176,193 | 0 | 0% | 2024-12-31 |
| Xtx Topco Ltd | $135.00 | 0.37% | 160,807 | +136,818 | +570.34% | 2024-12-31 |
| Fil Ltd | $109.00 | 0.29% | 129,579 | 0 | 0% | 2024-12-31 |